Join the Venous Thromboembolism group to help and get support from people like you.
Venous Thromboembolism News
Rate of Venous Thromboembolism Increased With Cancer Surgery
FRIDAY, Feb. 2, 2024 – The rate of venous thromboembolism is increased in association with cancer surgery, according to a study published online Feb. 2 in JAMA Network Open. Johan Björklund, M.D., ...
Link Explored for NSAID Use, Hormonal Contraception, VTE Risk
MONDAY, Sept. 11, 2023 – In women of reproductive age, nonsteroidal anti-inflammatory drug (NSAID) use is associated with venous thromboembolism, with significantly more additional events with...
Combo of Certain Birth Control Pills, Painkillers Could Raise Women's Clot Risk
FRIDAY, Sept. 8, 2023 – It's well known that certain forms of birth control carry a small risk of blood clots. Now a large new study suggests that some common painkillers can magnify that risk. The...
Apixaban Has Lower Bleeding Risk for Initial Anticoagulation for Venous Thromboembolism
TUESDAY, Sept. 5, 2023 – Apixaban has a lower bleeding risk than warfarin or rivaroxaban during initial treatment for patients with venous thromboembolism (VTE), according to a study published...
Prolonged Direct Oral Anticoagulants Beneficial for Preventing Recurrent VTE
MONDAY, Aug. 21, 2023 – For patients with venous thromboembolism (VTE) continuing warfarin or direct oral anticoagulants (DOACs) beyond six months, the risk for recurrent VTE is lower with DOACs,...
New Report Measures Scope of Damage From Medical Mistakes
THURSDAY, July 20, 2023 – About 795,000 Americans die or are permanently disabled every year due to misdiagnosed medical conditions. A new analysis led by experts at Johns Hopkins Medicine in...
Benefits of Indefinite Anticoagulant Unclear After First VTE
THURSDAY, June 29, 2023 – For patients with a first unprovoked venous thromboembolism (VTE), indefinite anticoagulation prevents some recurrent VTE events but induces additional major bleeding...
ASCO: Direct Oral Anticoagulant Therapy Feasible for Cancer Patients
TUESDAY, June 6, 2023 – Direct oral anticoagulant (DOAC) treatment is noninferior to low-molecular-weight heparin (LMWH) for preventing recurrent venous thromboembolism (VTE) in cancer patients,...
Atopic Dermatitis Tied to Higher Venous Thromboembolism Risk
WEDNESDAY, May 31, 2023 – Atopic dermatitis (AD) in adulthood is associated with an increased risk for venous thromboembolism (VTE), according to a study published online May 31 in JAMA Dermatology....
FDA Approves Two New Indications for Xarelto (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, Dec. 20, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved two pediatric indications for X...
FDA Approves Pradaxa (dabigatran) as First Oral Blood Thinning Medication for Children
June 21, 2021 – Today, the U.S. Food and Drug Administration approved Pradaxa (dabigatran etexilate) oral pellets to treat children 3 months to less than 12 years old with venous thromboembolism (a...
FDA Approves Fragmin (dalteparin sodium) as First Anticoagulant for Venous Thromboembolism in Pediatric Patients
May 16, 2019 – The U.S. Food and Drug Administration today approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE)...
FDA Approves New 10 mg Dosing for Xarelto (rivaroxaban) to Reduce the Continued Risk of Venous Thromboembolism (VTE)
TITUSVILLE, NJ, OCTOBER 30, 2017 – Janssen Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration (FDA) approved the 10 mg once-daily dose of Xarelto (rivaroxaban) for reducing t...
FDA Approves Bevyxxa (betrixaban) for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
SOUTH SAN FRANCISCO, Calif., June 23, 2017 (GLOBE NEWSWIRE) – Portola Pharmaceuticals Inc.® (Nasdaq:PTLA) today announced the U.S. Food and Drug Administration (FDA) has approved Bevyxxa ...
FDA Medwatch Alert: Eliquis (apixaban) 5 mg tablets: Recall One Lot- Bottle labeled as Eliquis 5 mg was found to contain Eliquis 2.5 mg tablets
ISSUE: Bristol-Myers Squibb Company is voluntarily recalling one lot (#HN0063) of Eliquis 5 mg tablets to the consumer level. This lot was distributed nationwide in the U.S. to wholesalers and retail...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Deep Vein Thrombosis (DVT), Deep Vein Thrombosis, Pulmonary Embolism